Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.

Literature DB >> 22101180

Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.

Jonah J Scott-McKean¹, Alberto C S Costa.

Abstract

The Ts65Dn mouse is the best-studied animal model for Down syndrome. In the experiments described here, NMDA-mediated or mGluR-mediated LTD was induced in the CA1 region of hippocampal slices from Ts65Dn and euploid control mice by bath application of 20 µM NMDA for 3 min and 50 µM DHPG for 5 min, respectively. We found that Ts65Dn mice display exaggerated NMDA-induced, but not mGluR-induced, LTD in the CA1 region of the hippocampus compared with euploid control animals. In addition, this abnormal level of LTD can be pharmacologically rescued by the NMDA receptor antagonist memantine.

Entities: Chemical Gene Species

Mesh：

Substances：

Year: 2011 PMID： 22101180 PMCID： PMC3222894 DOI： 10.1101/lm.024182.111

Source DB: PubMed Journal: Learn Mem ISSN： 1072-0502 Impact factor: 2.460

38 in total

1. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome.

Authors: R J Siarey; E J Carlson; C J Epstein; A Balbo; S I Rapoport; Z Galdzicki
Journal: Neuropharmacology Date: 1999-12 Impact factor: 5.250

2. Excitatory synaptic transmission mediated by NMDA receptors is more sensitive to isoflurane than are non-NMDA receptor-mediated responses.

Authors: K Nishikawa; M B MacIver
Journal: Anesthesiology Date: 2000-01 Impact factor: 7.892

Review 3. AMPA receptor trafficking and synaptic plasticity.

Authors: Roberto Malinow; Robert C Malenka
Journal: Annu Rev Neurosci Date: 2002-03-04 Impact factor: 12.449

4. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia.

Authors: Tsuyoshi Miyakawa; Lorene M Leiter; David J Gerber; Raul R Gainetdinov; Tatyana D Sotnikova; Hongkui Zeng; Marc G Caron; Susumu Tonegawa
Journal: Proc Natl Acad Sci U S A Date: 2003-07-08 Impact factor: 11.205

Review 5. LTP and LTD: an embarrassment of riches.

Authors: Robert C Malenka; Mark F Bear
Journal: Neuron Date: 2004-09-30 Impact factor: 17.173

6. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.

Authors: V Brown; P Jin; S Ceman; J C Darnell; W T O'Donnell; S A Tenenbaum; X Jin; Y Feng; K D Wilkinson; J D Keene; R B Darnell; S T Warren
Journal: Cell Date: 2001-11-16 Impact factor: 41.582

7. Altered synaptic plasticity in a mouse model of fragile X mental retardation.

Authors: Kimberly M Huber; Sean M Gallagher; Stephen T Warren; Mark F Bear
Journal: Proc Natl Acad Sci U S A Date: 2002-05-28 Impact factor: 11.205

8. A mouse model for Down syndrome exhibits learning and behaviour deficits.

Authors: R H Reeves; N G Irving; T H Moran; A Wohn; C Kitt; S S Sisodia; C Schmidt; R T Bronson; M T Davisson
Journal: Nat Genet Date: 1995-10 Impact factor: 38.330

9. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.

Authors: Alexander M Kleschevnikov; Pavel V Belichenko; Angela J Villar; Charles J Epstein; Robert C Malenka; William C Mobley
Journal: J Neurosci Date: 2004-09-15 Impact factor: 6.167

Review 10. The mGluR theory of fragile X mental retardation.

Authors: Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal: Trends Neurosci Date: 2004-07 Impact factor: 13.837

21 in total

1. Altered distribution of hippocampal interneurons in the murine Down Syndrome model Ts65Dn.

Authors: Samuel Hernández-González; Raúl Ballestín; Rosa López-Hidalgo; Javier Gilabert-Juan; José Miguel Blasco-Ibáñez; Carlos Crespo; Juan Nácher; Emilio Varea
Journal: Neurochem Res Date: 2014-11-16 Impact factor: 3.996

2. Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.

Authors: Alberto C Costa
Journal: Nat Rev Neurol Date: 2012-03-13 Impact factor: 42.937

Review 3. Prospects for improving brain function in individuals with Down syndrome.

Authors: Alberto C S Costa; Jonah J Scott-McKean
Journal: CNS Drugs Date: 2013-09 Impact factor: 5.749

4. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome.

Authors: Gurjinder Kaur; Ajay Sharma; Wenjin Xu; Scott Gerum; Melissa J Alldred; Shivakumar Subbanna; Balapal S Basavarajappa; Monika Pawlik; Masuo Ohno; Stephen D Ginsberg; Donald A Wilson; David N Guilfoyle; Efrat Levy
Journal: J Neurosci Date: 2014-04-09 Impact factor: 6.167

Review 5. Dendritic spine dysgenesis in autism related disorders.

Authors: Mary Phillips; Lucas Pozzo-Miller
Journal: Neurosci Lett Date: 2015-01-08 Impact factor: 3.046

6. AKAP150-anchored calcineurin regulates synaptic plasticity by limiting synaptic incorporation of Ca2+-permeable AMPA receptors.

Authors: Jennifer L Sanderson; Jessica A Gorski; Emily S Gibson; Philip Lam; Ronald K Freund; Wallace S Chick; Mark L Dell'Acqua
Journal: J Neurosci Date: 2012-10-24 Impact factor: 6.167

Review 10. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.

Authors: Nathan Cramer; Zygmunt Galdzicki
Journal: Neural Plast Date: 2012-07-12 Impact factor: 3.599